Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

By C. A. Dinarello. Blood, 2011

2,285 citations recorded by the source corpus.

Subfields: Hematology, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/c1b58cf07b6dc178185d8ee7b0b3eb5497f315c1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. A. Mantovani
2. C. Garlanda
3. P. Ridker
4. E. L. Kachikwu
5. W. McBride
6. D. Schaue
7. S. Toldo
8. Antonio Abbate

In Immunology

1. C. Garlanda
2. A. Mantovani
3. P. Ridker
4. C. A. Dinarello
5. W. McBride
6. D. Schaue
7. E. L. Kachikwu
8. Shinwan Kany

In Molecular Biology

1. C. Garlanda
2. A. Mantovani
3. P. Ridker
4. E. L. Kachikwu
5. W. McBride
6. D. Schaue
7. Shinwan Kany
8. B. Relja

Citations in the corpus

• Repurposing mitochondria from ATP production to ROS generation drives a pro-inflammatory phenotype in macrophages that depends on succinate oxidation by complex II (2016, background): “For example, DMM may be useful in the treatment of inflammatory diseases in which IL-1b has been linked to pathogenesis (Dinarello, 2011).”
• Cytokines in Inflammatory Disease (2019, background): “The soluble decoy receptor IL-1R2 functions as a receptor in plasma, and limits spreading of IL-1α, thereby reducing its signaling and restraining inflammation [66].”
• From CRP to IL-6 to IL-1: Moving Upstream To Identify Novel Targets for Atheroprotection (2016, background): “lines are the critical dysfunctional cells that promote pathologic inflammation.(64) This is an important distinction from”
• THE INTERLEUKIN-1 FAMILY: BACK TO THE FUTURE (2013, positive): “Extracellular cleavage of the inactive IL-1b precursor by neutrophil enzymes such a proteinase-3 and elastase generate active IL-1b because the cleavage site is close to that of caspase-1 (Dinarello, 2011).”
• The NLRP3 inflammasome in acute myocardial infarction (2018, background): “DHART (2014) Stable NYHA class II–III diastolic HF with LVEF >50% and CRP >2 mg/l (12) Randomized, double-blind, crossover trial of anakinra versus placebo for 2 weeks (100 mg given once daily for 2 weeks) • Reduction in CRP levels • Improvement in peak aerobic exercise capacity at 2 weeks • Improve”
• Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions (2022, background): “The IL-1 family constitutes a huge and complex network of pleiotropic pro-inflammatory cytokines closely involved in regulating immune cells and inflammatory processes.(236) Among IL-1 family members, IL-1α, IL-1β, and IL-1Rα have been studied in detail in relation to ischemic stroke.”
• Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial (2016, background): ““Sepsis” constitutes various degrees of systemic inflammation in the context of microbial infection (1), with production of proinflammatory cytokines including interleukin-1 (IL-1), IL-6, IL-18, and tumor necrosis factor (2, 3).”
• Cytokines in Radiobiological Responses: A Review (2012, positive): “Recombinant IL-1R antagonist (Anakinra) or soluble IL1R (Rilonacept) have been used to identify patients with such diseases and to distinguish them from those that respond better to anti-TNF therapies, such as infliximab (anti-TNF) or etanercept (TNFR2-IgG1 fusion product) (83).”